Business
Endonovo Therapeutics Announces Partnership with Second Hospital
Endonovo Therapeutics Announces Partnership with Second Hospital.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\nLOS ANGELES, CA , March 29, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) (\"Endonovo\" or the \"Company\"), today announced an agreement with a nationally recognized hospital group to enhance the quality of the healthcare/patient experience through the use of its electroceutical therapeutic device, SofPulse®. Endonovo has been approved to provide the hospital with an initial order of SofPulse® devices for use in the hospital and expects continued follow-on orders for additional SofPulse® units.\n Alan Collier, Endonovo’s Chief Executive Officer, stated “We are excited to work with a second hospital group and continue to expand our ability to improve the patient postoperative experience. We are in discussions with several other hospital groups and medical facilities to bring the SofPulse® unique technology to the market in the near future. We anticipate this latest relationship will provide a better recovery and better outcomes for patients. We also believe this second hospital group further validates SofPulse® efficacy in wound healing and pain management through past and proven results. We continue to expand the SofPulse® network with our leadership team, partners and the collective desire to be out-in-front with value-based health care. Together, we’re transforming how people get the care they need.” “With the opioid epidemic at its current levels, SofPulse® provides the alternative to postoperative pain management people are demanding today.” continued Mr. Collier. About Endonovo Therapeutics Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™ therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ therapeutic device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative...